Search Results
Baxter Declares Quarterly Dividend
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.245 per share of common stock. The dividend is payable on April 1, 2021, to shareholders of record as of February 26, 2021. The indicated annual dividend rate is $0.98 per share of common stock. About Baxter
Baxter Appoints Dr. David Wilkes to Its Board and Albert Stroucken as Lead Independent Director
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced it has appointed David S. Wilkes, M.D., dean, University of Virginia School of Medicine, and co-founder and chief scientific officer of biotech start-up ImmuneWorks Inc., to its board of directors. Dr. Wilkes will serve on Baxter's Quality, Compliance and Technology Committee. Additionally, Baxter has appointed Albert P.L.
American Diabetes Association and the Baxter International Foundation Partner in Health Equity Initiative to Address Barriers to Diabetes Management
Today, the American Diabetes Association® (ADA) and the Baxter International Foundation, the philanthropic arm of Baxter International Inc., announced a new partnership as part of the ADA’s Health Equity Now (HEN) platform to address health disparities for people with diabetes in Chicago’s underserved Black communities.
Baxter Reports Fourth-Quarter and Full-Year 2020 Results
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the fourth quarter and full year ended December 31, 2020, and provided its financial guidance for 2021.
Fluid Responsiveness and Why it Matters for Patients
How a dynamic measurement can inform clinical decisions and personalize care
Baxter to Present at SVB Leerink 10th Annual Global Healthcare Conference
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:40 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through May 25, 2021.
Baxter BioPharma Solutions Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine
Baxter International Inc. (NYSE: BAX), a global leader in sterile medication production and delivery, today announced that Baxter BioPharma Solutions (BPS) has entered into an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax’ COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M™ adjuvant. Baxter BioPharma Solutions is a premier contract manufacturing organization that specializes in parenteral (injectable) pharmaceuticals, including vaccines.
Baxter Suspends PAC Contributions Following Acts of Violence at U.S. Capitol
Baxter has temporarily suspended contributions from its political action committee (PAC), which is funded by voluntary employee contributions, to current members of U.S. Congress. This decision is in response to the violence and unlawful acts that occurred at the U.S. Capitol on January 6. Baxter condemns these violent acts and calls on members of Congress and all of our nation’s leaders to work together to unite the country and help us move forward together.
Baxter to Host Fourth-Quarter 2020 Financial Results Conference Call for Investors
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its fourth-quarter 2020 financial results on Thursday, February 4, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/5044187 to pre-register for the call and receive the call information.